Core Viewpoint - The third China International Supply Chain Promotion Expo showcases the innovative strength and green practices of the cotton industry, with a focus on global sourcing, production, and sales by companies like Steady Medical and Cotton Era [2][3]. Group 1: Event Overview - The expo opened on July 16, featuring Steady Medical and its brand Cotton Era, highlighting the theme "Global Good Cotton, One Cotton One World" [2]. - The event attracted significant attention with immersive experiences such as "Cotton Stories" and real-time connections to production facilities [2][3]. Group 2: Global Production and Market Expansion - The "Global Production" interactive area allowed attendees to witness the transformation of raw cotton into high-quality medical and cotton products [3]. - Steady Medical is expanding its global footprint by investing in production bases in North America and Southeast Asia, while Cotton Era is focusing on the Southeast Asian market and exploring entry into the Middle East and Europe [3]. Group 3: Green Initiatives and Collaborations - A joint initiative called the "Green Win Chain Initiative" was launched, promoting sustainable cooperation in the health sector and enhancing the "green content" of supply chains [3]. - Steady Medical introduced a "Green Operating Room" solution aimed at replacing synthetic materials with cotton, enhancing safety and efficiency in medical settings [4]. Group 4: Technological Innovations - Cotton Era is innovating with core materials like cotton non-woven fabric and gauze, significantly improving production efficiency and expanding applications in daily life [5][6]. - The company’s Cotton Tech continues to push boundaries in softness, breathability, and sustainability, promoting a "cotton lifestyle" as a new choice for comfort and health [6]. Group 5: Future Directions - Both companies aim to deepen their strategies of product leadership, operational excellence, and global vision, positioning Chinese cotton as a "green business card" on the international stage [6].

Industry Outlook - The third-party medical diagnostic service industry is rapidly developing, with ICL expected to benefit from cost and technology advantages [3] - ICL's chain operators have a broader laboratory network compared to hospital laboratories, allowing for lower costs and more testing projects [3] - New technologies such as AI pathology diagnosis and automated laboratory systems are anticipated to reshape the industry [3] Financial Performance - In 2024, the company achieved a revenue of CNY 174,218.10 million, a year-on-year increase of 4.05% [9] - The medical diagnostic service revenue was CNY 79,716.65 million, growing by 23.26%, contributing significantly to overall revenue growth [9] - The company reported a net profit of -CNY 10,943.62 million, a reduction in losses by 22.71% compared to the previous year [9] Operational Strategies - The company is focusing on digital transformation and information technology to enhance operational efficiency and service quality [5] - A dual-driven business model is being implemented to achieve full-process digitalization from sample receipt to laboratory testing [5] - The company aims to diversify its supplier base to mitigate risks associated with reliance on major suppliers, which account for 65.28% of procurement [6] Future Growth Drivers - The main growth drivers include stable revenue from core business operations and effective management of operational costs [5] - The company plans to enhance its capabilities in CRO (Contract Research Organization) and scientific services, which are showing growth potential [10] - Continued investment in AI medical applications is expected to create new revenue streams, although profitability in this area has not yet been achieved [11] Environmental Initiatives - The company is committed to energy management and has set specific goals for reducing emissions related to laboratory energy consumption and hazardous material transport [12] - A cold chain logistics system has been established to ensure safe and efficient transportation of clinical samples and medical devices [10] Challenges and Responses - The industry faces pressure from healthcare cost control measures, prompting the company to enhance its business model and expand its marketing network [12] - The company is adapting to seasonal revenue fluctuations and aims to stabilize profitability through improved operational efficiency [8]